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Abstract
Background: Interstitial cystitis (IC) is a chronic bladder disorder, with symptoms including pelvic
and or perineal pain, urinary frequency, and urgency. The etiology of IC is unknown, but sensitive
and specific biomarkers have been described, including antiproliferative factor (APF), heparin-
binding epidermal growth factor-like growth factor (HB-EGF), and epidermal growth factor (EGF).
However, the relative sensitivity of these biomarkers in ulcerative vs. nonulcerative IC is unknown,
and these markers have yet to be validated in another laboratory. We therefore measured these
markers in urine from patients with or without Hunner's ulcer, as well as normal controls, patients
with bladder cancer, and patients with bacterial cystitis, at the First Hospital of China Medical
University.
Methods: Urine specimens were collected from two groups of Chinese IC patients (38 IC patients
with Hunner's ulcers, 26 IC patients without Hunner's ulcers), 30 normal controls, 10 bacterial
cystitis patients and 10 bladder cancer patients. APF activity was determined by measuring 3H-
thymidine incorporation in vitro, and HB-EGF and EGF levels were determined by ELISA.
Results: APF activity (inhibition of thymidine incorporation) was significantly greater in all IC
patient urine specimens than in normal control specimens or in specimens from patients with
bacterial cystitis or bladder cancer (p < 0.0001 for each comparison). Urine HB-EGF levels were
also significantly lower and EGF levels significantly higher in both groups of IC patients than in the
three control groups (p < 0.0001 for each comparison). Although APF and HB-EGF levels were
similar in ulcerative and nonulcerative IC patients, EGF levels were significantly higher in IC patients
with vs. without ulcers (p < 0.004).
Conclusion: These findings indicate that APF, HB-EGF and EGF are good biomarkers for both
ulcerative and nonulcerative IC and validate their measurement as biomarkers for IC in Chinese
patients.
Background
Interstitial cystitis (IC) is a chronic bladder disorder, with
symptoms including pelvic and or perineal pain, urinary
frequency, and urgency [1]. The cause of IC is unknown,
and IC is therefore generally diagnosed by the presence of
certain clinical features in the absence of other identifiable
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causes for the symptoms (such as urinary tract infection)
[2]. Patients may undergo a history, physical examination,
urinalysis, urine culture, urodynamics, and cystoscopy
under anesthesia with bladder distention during the
work-up for IC. All the results of these tests are combined
with the clinical judgment of the practitioner to make the
diagnosis.
Three biomarkers have been described for IC in various
patient groups including Chinese IC patients [3-5]. The
first one is antiproliferative factor (APF), a low molecular
weight frizzled-8 related peptide [6] that inhibits the
growth of bladder epithelial cells. APF activity is found in
the urine of over 90% of patients clinically diagnosed with
IC [4,5]. The second biomarker is heparin-binding epider-
mal growth factor-like growth factor (HB-EGF), which is
important for epithelial cell proliferation and wound
healing. This factor is significantly decreased in urine from
IC patients when compared with specimens from normal
controls or patients with other urological conditions
[4,5]. A third biomarker is epidermal growth factor (EGF),
which is significantly increased in urine from IC patients
when compared with the same control groups [4,5].
In this article we describe studies to determine the relative
sensitivity of these markers in patients with ulcerative vs.
nonulcerative IC. We also sought to confirm their utility
in Chinese patients by measuring these factors in our lab-
oratory using specimens from a group of Chinese IC
patients who were not previously studied, as well as nor-
mal controls, and patients with bacterial cystitis or blad-
der cancer.
Methods
Patients
Two groups of Chinese IC patients who had previously
undergone diagnostic cystoscopy and fulfilled the NIDDK
diagnostic criteria for IC were studied; the first group
included 38 IC patients had Hunner's ulcers, and the sec-
ond group included 26 IC patients who did not have Hun-
ner's ulcers [2]. Normal controls were hospital personnel
with no known urinary tract disease, who were matched
as a group to the IC patients by gender and age. Urine was
also obtained from bacterial cystitis and bladder cancer
patients for comparison. IC patients were asked questions
about symptoms and related problems from the O'Leary-
Sant questionnaire [7], and total symptom index and
problem index scores determined. All urine samples were
collected at the First Hospital of China Medical University
in the Shenyang City of the Peoples Republic of China. All
participants were at least 18 years old and were enrolled
in accordance with guidelines of the Institutional Review
Board of China Medical University.
Urine specimens
Clean-catch urine specimens were obtained in which each
IC patient or control wiped the labial area with 10% pov-
idone iodine solution and then collected a midstream
urine into a sterile container. Specimens were initially
kept at 4°C, then transported to the laboratory where cel-
lular debris was removed by low speed centrifugation at
4°C, aliquoted under sterile conditions, and stored at -
80°C until used.
Cell culture
Adult human bladder epithelial (HBE) cells were grown
from cadaveric bladder tissue of a young (30 year old)
female accident victim who had no history of bladder dis-
order. These cells were grown in DMEM-F12 medium con-
taining 10% fetal bovine serum (FBS), 1% antibiotic/
antimycotic solution, 1% glutamine, and 1.0 u/ml insulin
(all from Sigma) at 37°C in a 5% CO2 atmosphere.
3H-thymidine incorporation
3H-thymidine incorporation was assayed as previously
described by Keay, et al [4]. HBE cells were plated at a den-
sity of 1 × 104 cell per well onto 96 well tissue culture
plates and incubated at 37°C overnight. The medium was
then changed to MEM containing only 1% glutamine and
1% antibiotic/antimycotic solution, and the cells were
incubated at 37°C overnight. On the third day, urine spec-
imens from IC patients or controls were corrected to pH
7.2 and 300 mOSM, filtered through a 0.2 uM pore filter
(Gelman Science, Ann Arbor, MI), diluted 1:2 in MEM
(Serum-free MEM containing only glutamine and antibi-
otics/antimycotics) and applied to the cells; cell controls
received serum free MEM medium only. After 48 hours of
incubation at 37°C the cells were labeled with 1 uCi per
well 3H-thymidine (NEN DuPont, Wilmington, DE) and
incubated for another 4 hours at 37°C. Cells were then
trypsinized and insoluble cell contents harvested and
methanol-fixed onto glass filber filter paper, as previously
described. The amount of radioactivity incorporated was
determined as counts per minute using a Tri-Carb 2900
TR Scintillation counter (Packard Bioscience). A signifi-
cant inhibition of 3H-thymidine incorporation was
defined as a mean decrease in counts per minute of greater
than 2 standard deviations from the mean of control cells
for each plate.
Enzyme-linked immunosorbent assays
HB-EGF
Each well of a 96 well Immulon II plate (Dynatech Labo-
ratories, Chantilly, VA) was coated with 200 ul urine at
4°C overnight as previously described by Keay, et al [4].
The next day the plate was washed 5 times with 1× PBS
buffer, the plates were blocked with 5% FBS/1 mM EDTA/
0.05% Tween 20 in 1× PBS buffer. Anti-HB-EGF antibody
(1 ug/ml; R & D systems, Minneapolis, MN) was addedBMC Urology 2005, 5:7 http://www.biomedcentral.com/1471-2490/5/7
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and the plates were incubated for 2 hours at 37°C. After
an additional 5 washes, biotinylated anti-goat IgG/avidin
D horseradish peroxidase (HRP) was added and plates
were incubated for 1.5 hours at room temperature,
washed, and developed with ABTS (2.2'-Azino-bis-(3-
ethylbenzothiazoline-6-sulfonic)) substrate; absorbance
was read at 405 nm.
EGF
Urine from IC patients and controls was diluted 1:200 in
RD5E diluent and pipetted into wells precoated with
monoclonal anti-EGF antibody, according to the manu-
facturer's instructions (R&D Systems). After incubation at
room temperature for 2 hours, plates were rinsed with
wash buffer and incubated further with HRP-linked poly-
clonal anti-goat antibody, rinsed again, and developed
using tetramethylbenzidine (TMB) substrate. Develop-
ment was stopped with 2 N sulfuric acid, and absorbance
read at 450 nm.
Linear absorbance versus concentration curves were pre-
pared from results with known standard concentrations of
EGF or HB-EGF (R & D Systems), and sample concentra-
tions were determined by plotting absorbance values.
Statistical analysis
The comparisons of mean change in 3H-thymidine incor-
poration and growth factor levels in urine specimens from
patients with IC vs. controls were made using a two-tailed
student t test.
Results
Antiproliferative factor activity in urine specimens
To compare the effect of urine specimens from IC patients
and controls on bladder epithelial cell proliferation, we
measured 3H-thymidine incorporation in normal human
bladder epithelial cells. Specimens were collected from
two groups of Chinese IC patients, 38 IC patients with
Hunner's ulcers, 26 IC patients without Hunner's ulcers,
30 normal controls, 10 bacterial cystitis patients and 10
bladder cancer patients, by the clean catch method. As
shown in the table, IC patients and normal controls did
not differ significantly in age or gender; most of the IC
patients and normal controls were women, with five men
in both IC groups, and two men in the normal control
group.
HBE cells exposed to urine from the 38 Chinese IC
patients with Hunner's ulcers had significantly less 3H-
thymidine incorporation than cells incubated with urine
from normal controls (-82.1 ± 2.2% vs. 1.6 ± 3.5%, p <
0.000001) (Figure 1), and cells exposed to urine from the
26 Chinese IC patients without Hunner's ulcers also had
significantly less 3H-thymidine incorporation than cells
incubated with urine from normal controls (-78.5 ± 2.8%
vs. 1.6 ± 3.5%, p < 0.000001). The two groups of IC
patients did not differ significantly from each other (p =
0.13). In comparison, HBE cells exposed to urine from
bacterial cystitis or bladder cancer patients did not differ
significantly from cells incubated with urine from normal
controls (-8.4 ± 6.5%, and -8.5 ± 5.3% vs. 1.6 ± 3.5%), but
each differed significantly from cells cultured with IC
patients urine (p < 0.0001). When inhibition of thymi-
dine incorporation greater than 2 standard deviations
from the mean of cell controls was used as the definition
for APF activity, 59/64 (92%) of IC patients had evidence
for APF activity vs. only 1/30 (3%) of normal controls.
None of the samples from bacterial cystitis or bladder can-
cer patients had any evidence for APF activity.
Levels of HB-EGF and EGF in urine from IC patients and 
normal controls
We next measured HB-EGF and EGF levels in urine speci-
mens from the same Chinese IC patients, normal con-
trols, bacterial cystitis patients and bladder cancer patients
by ELISA. As shown in Figure 2, the concentration of urine
HB-EGF was significantly lower in the 38 IC patients with
Hunner's ulcers (1.19 ± 0.20 ng/ml) and in the 26 IC
patients without Hunner's ulcers (1.42 ± 0.23 ng/ml) as
compared to normal controls (9.28 ± 1.04 ng/ml) or
patients with bacterial cystitis or bladder cancer (5.34 ±
1.19 ng/ml, and 5.72 ± 0.87 ng/ml, p < 0.0001 for com-
parison of each IC group to each control group). Mean
HB-EGF levels in the two groups of IC patients did not dif-
fer significantly from each other (p = 0.43). The mean
concentration of urine EGF (Figure 3), however, was sig-
nificantly higher in 38 IC patients with Hunner's ulcers
(21.90 ± 1.19 ng/ml) than in 26 IC patients without Hun-
ner's ulcers (16.32 ± 1.44 ng/ml) (p <0.004), and was
markedly higher for both IC groups as compared to nor-
mal controls (6.49 ± 0.57 ng/ml) or patients with bacte-
rial cystitis or bladder cancer (6.32 ± 1.26 ng/ml, and 8.03
± 1.95 ng/ml, p < 0.0001 for comparison of each IC group
to each control group).
Discussion
This report presents evidence that three urine biomarkers
for IC (APF, HB-EGF and EGF) were confirmed by meas-
urement in our laboratory at First Hospital of China Med-
ical University using bladder epithelial cells from Chinese
normal controls and urine specimens from a new group of
Chinese IC patients and controls that had not previously
been studied. Our data were comparable to those pub-
lished previously [3-5], with 92% of IC patients having
APF activity as compared to only 3% of controls.
APF is a low molecular weight peptide made by bladder
epithelial cells from IC patients that inhibits the prolifer-
ation of human bladder epithelial cells [6,8], suggesting
that it may cause the bladder epithelial thinning orBMC Urology 2005, 5:7 http://www.biomedcentral.com/1471-2490/5/7
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ulceration common in IC [9]. Bladder cell proliferation is
also known to be influenced by growth factors and their
regulatory proteins. HB-EGF has been shown to be impor-
tant for replication of a variety of epithelial cells including
hepatocytes, keratinocytes, gastric epithelial cells, and
uterine epithelial cells and is known to stimulate bladder
epithelial replication in vitro [10]. It is therefore possible
that decreased synthesis of HB-EGF by epithelial or other
bladder cells contributes to the pathogenesis of IC by
impairing normal bladder epithelial regeneration. APF
can inhibit HB-EGF production by bladder epithelial cells
[8], indicating a possible mechanism for APF's antiprolif-
erative activity.
The reproducibility of APF, HB-EGF and EGF as biomark-
ers for IC in our patients indicates that one or more of
these factors may be useful for the diagnosis of IC in
patients from various racial backgrounds, and measured
in different laboratories. As previously reported by Keay,
et al [11], these biomarkers can clearly distinguish
between IC and control groups whether they are normal-
ized to urine creatinine or urine volume [11]. We
therefore normalized the levels to urine volume for our
study. We also compared APF, HB-EGF and EGF levels in
IC patients with Hunner's ulcers vs. IC patients without
Hunner's ulcers, and determined that mean values for all
three markers were more abnormal in patients with ulcers,
although the difference between IC patients with Hun-
ner's ulcers and IC patients without Hunner's ulcers was
only statistically significant for EGF in this study. Whether
this finding indicates that ulcerative IC is a more severe
form of the disorder than nonulcerative IC requires fur-
ther investigation.
Several biomarkers have been described for IC as recently
reviewed [12]. GP51, a glycoprotein urinary marker,
reportedly is also specific for IC [13], but additional stud-
ies have not been done on this marker. Nitric oxide
APF activity in urine from Chinese interstitial cystitis patients with Hunner's ulcers (IC-U), Chinese interstitial cystitis patients  without Hunner's ulcers (IC-N), normal controls (Ctr), and patients with bacterial cystitis (BC), or bladder cancer (BCa) Figure 1
APF activity in urine from Chinese interstitial cystitis patients with Hunner's ulcers (IC-U), Chinese interstitial cystitis patients 
without Hunner's ulcers (IC-N), normal controls (Ctr), and patients with bacterial cystitis (BC), or bladder cancer (BCa). APF 
activity was measured as inhibition of 3H-thymidine incorporation in normal bladder epithelial cells. Each data point indicates 
the mean change in incorporation, with each specimen tested in triplicate. Horizontal line indicates value of mean; vertical line 
indicates standard error of the mean for each group.
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synthase (NOS) stimulates the production of nitric oxide
(NO) which then increases cyclic GMP levels by activating
guanylyl cyclase. In some studies, female IC patients have
been shown to have significantly decreased NOS activity
in their urine cell pellet than female controls, and urinary
cyclic GMP levels were significantly lower in female IC
patients than in female controls or females with urinary
tract infections [5,14]. However, bladder luminal NO lev-
els have also been shown to be markedly increased in
patients with IC, and elevated bladder luminal NO levels
are not specific for IC [15,16] but also occur in patients
with various forms of cystitis. CD45RO positive lym-
phocytes are another biomarker for ulcerative IC patients.
They are not found in the urine of healthy subjects, but are
also found in bladder cancer patients treated with BCG
[17,18]. Although they also are not specific for IC, these
lymphocytes may be biomarkers that reflect the severity of
interstitial bladder inflammation.
Urine APF activity and levels of HB-EGF, EGF, IL-6 and
IGFBP3 were shown to be significantly different between
IC patients and normal controls in one large comparison
study [5]. However, APF, HB-EGF, and EGF were the most
sensitive and specific for IC, with anti-proliferative factor
activity most clearly separating the interstitial cystitis and
control groups (5).
HB-EGF levels in urine from IC patients, normal controls, bacterial cystitis patients and bladder cancer patients Figure 2
HB-EGF levels in urine from IC patients, normal controls, bacterial cystitis patients and bladder cancer patients. HB-EGF levels 
were measured by ELISA in urine specimens from interstitial cystitis patients with Hunner's ulcers (IC-U), interstitial cystitis 
patients without Hunner's ulcers (IC-N), asymptomatic controls (Ctr), and patients with bacterial cystitis (BC), or bladder can-
cer (BCa). Each data point is the mean value for duplicate specimens. Horizontal line indicates value of mean; vertical line indi-
cates standard error of mean for each group.
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EGF levels in urine from IC patients, normal controls, bacterial cystitis patients and bladder cancer patients Figure 3
EGF levels in urine from IC patients, normal controls, bacterial cystitis patients and bladder cancer patients. EGF levels were 
measured by ELISA in urine specimens from interstitial cystitis patients with Hunner's ulcers (IC-U), interstitial cystitis patients 
without Hunner's ulcers (IC-N), asymptomatic controls (Ctr), and patients with bacterial cystitis (BC), or bladder cancer 
(BCa). Each data point is the mean value for duplicate specimens. Horizontal line indicates value of mean; vertical line indicates 
standard error of mean for each group.
Table 1: Patient Characteristics
IC-U* IC-N+ Control BC‡ BCa†
Age 41 ± 11.1 46 ± 10.6 36.6 ± 8.8 36.4 ± 9.6 55.4 ± 7.1
Gender (F/M) 36/2 23/3 28/2 8/2 3/7
Symptom Index Score points 19.6 ± 0.12 18.9 ± 0.29 - - -
Problem Index Score points 15.7 ± 0.15 15.5 ± 0.21 - - -
Average voiding volume (ml) 95 ± 15 98 ± 18 - - -
Average bladder capacity (ml)# 205 ± 16 216+17 - - -
* IC-U = IC patients with Hunner's ulcers
+ IC-N = IC patients without Hunner's ulcers
‡ BC = Bacterial Cystitis
† BCa = Bladder Cancer
# Bladder capacity determined while patients were awake, prior to distension
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Conclusion
APF, HB-EGF and EGF have now been confirmed as good
biomarkers for IC by another laboratory. Furthermore, we
provide the first evidence that these IC biomarkers are
present in both the urine of patients with ulcerative as
well as nonulcerative IC, and the first comparison of these
markers between these two groups of IC patients.
Although EGF levels were significantly more abnormal in
ulcerative than nonulcerative patients, APF and HB-EGF
were not significantly different between the two groups,
and the clinical significance of the differences in EGF lev-
els is therefore uncertain at this time.
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